OS Therapies partners with Eversana for U.S. commercialization of OST-HER2

OS Therapies (OSTX) has selected Eversana, a provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma. OS Therapies is a clinical-stage cancer immunotherapy company dedicated to developing a new way of activating the immune system to kill cancers that express HER2 like Osteosarcoma, Breast Cancer, Colorectal Cancer and other solid tumors. OST-HER2 is the first potential new treatment in over 40 years for pediatric osteosarcoma, a rare, aggressive bone cancer that often metastasizes to the lungs, primarily affecting children and adolescents. The therapy has received Orphan, Fast Track and Rare Pediatric Disease Designations from the FDA, with a Biologics License Application rolling submission targeted to begin in Q3, with potential approval coming as early as year end 2025.